AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT05511051
Drug: HAIC
RxNorm normalized name: Hepatic Arterial Infusion Chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HAIC
Trial: NCT05151146
Drug: ANJ900
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin hydrochloride delayed-release tablets
Trial: NCT05982392
Drug: Naproxen Sodium
RxNorm normalized name: Naproxen Sodium
DrugBank: Naproxen (DB00788)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Naproxen sodium 550mg will be given 60 minutes before start of procedure.
Trial: NCT05982392
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be given 60 minutes before start of procedure.
Trial: NCT05390944
Drug: IMP4297(20mg)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral dose of IMP4297 administered under fasting conditions 5\*20 mg capsules in first intervention period and 10\*10 mg capsules in second intervention period (after washout period: at least 7 days)
Trial: NCT05390944
Drug: IMP4297(10mg)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral dose of IMP4297 administered under fasting conditions 10\*10 mg capsules in first intervention period and 5\*20 mg capsules in second intervention period (after washout period: at least 7 days)
Trial: NCT05241067
Drug: Normal Saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (Dose: equal volume saline) + Standard of care
Trial: NCT05549206
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline solution
Trial: NCT05312398
Drug: FOLFIRI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: I LINE:~- FOLFIRI + cetuximab~FOLFIRI: 200 mg L-folinic acid given concurrently with 180 mg/ m² irinotecan over 1.30 h IV infusion, followed by a 400 mg/ m² IV bolus of fluorouracil followed by 2400 mg/ m² fluorouracil IV infusion over 46 h every 14 days.~Cetuximab: 400 mg/m2 initial dose (120-minute IV infusion on cycle 1 day 1), then 250 mg/m2 once weekly thereafter
Trial: NCT05312398
Drug: FOLFOX regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: II LINE:~- FOLFOX + cetuximab~FOLFOX: 200 mg L-folinic acid given concurrently with 85 mg/ m² oxaliplatin over 2 h IV infusion, followed by a 400 mg/ m² IV bolus of fluorouracil followed by 2400 mg/ m² fluorouracil IV infusion over 46 h every 14 days.~Cetuximab: as I line
Trial: NCT06149507
Drug: Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prescribe the drug to the child
Trial: NCT06149507
Drug: Ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Prescribe the drug to the child
Trial: NCT05811975
Drug: KSX01-TCRT injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: individualization TCR-T cell injection
Trial: NCT06543290
Drug: Azithromycin Pill
RxNorm normalized name: azithromycin Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azithromycin 2 grams to be administered prior to start of induction for those randomized to the study arm
Trial: NCT05587400
Drug: inhaled nitric oxide
RxNorm normalized name: nitric oxide Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nitric oxide inhalation
Trial: NCT05689931
Drug: Standard inhaled corticosteroids (ICS) and long-acting beta 2 agonists (LABA)
RxNorm normalized name: Sinex Long-Acting Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine asthma treatment with inhaled corticosteroids (ICS) and long-acting beta 2 agonists (LABA)
Trial: NCT05416320
Drug: Subject's already prescribed drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will continue to use their already prescribed topical formulation once daily on the scalp. The subjects will use their treatment for a total of 6 months.
Trial: NCT06107673
Drug: Aromatase inhibitor
RxNorm normalized name: Aromatase inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AI: Take according to the instructions provided.
Trial: NCT06107673
Drug: Cyclophosphamide injection
RxNorm normalized name: cyclophosphamide Injection
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Administered as a 500 mg/m2 intravenous infusion. It is given every three weeks and dose reduction or treatment delay is allowed, up to a maximum delay of 3 weeks from the previous dose calculation. Treatment will be terminated if the delay exceeds this limit.
Trial: NCT05360576
Drug: LSP-5415 (etonogestrel/ethinyl estradiol vaginal ring)
RxNorm normalized name: ethinyl estradiol / etonogestrel Vaginal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: To prevent pregnancy
Trial: NCT05360576
Drug: NuvaRing Vaginal Ring
RxNorm normalized name: NuvaRing Vaginal Ring
FDA approved: no
EMA approved: no
PMDA approved: no
Description: To prevent pregnancy
Trial: NCT06274437
Drug: BND-35
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: Solution for infusion; Route of administration: Intravenous
Trial: NCT05163535
Drug: VM-1500A-LAI
RxNorm normalized name: laidlomycin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VM-1500A (parent drug of elsulfavirine) IM injection dosage form
Trial: NCT04983498
Drug: Lactated Ringers, Intravenous
RxNorm normalized name: Lactated Ringers, Intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Goal directed IV fluids to be administered starting preop per the NMH Colorectal ERAS protocol (LR @ 5mL/kg/hr).
Trial: NCT06478940
Drug: 3 mixtatin pulpotomy
RxNorm normalized name: HISTATIN 3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pulp treatment with applying 3mixture of antibiotic (Metronidazole, cefixime, and Ciprofloxacin) along with simvastatin
Trial: NCT06478940
Drug: MTA pulpotomy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pulp treatment with applying MTA
Trial: NCT04540406
Drug: NBT-NM108
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Taken in the form of drinks four times a day (before each main meal and 2 hours after dinner) for 28 days. Each drink is prepared by mixing one sachet (30 g) with 500 ml of water.
Trial: NCT04972175
Drug: 50-Hour Intervention - BC LisPram
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous-delivery of BC LisPram using pump therapy.
Trial: NCT06305546
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: For two weeks, all individuals were instructed to use pea-sized gel on their gingiva two times a day. To ensure patient compliance, we assigned patients with log sheets to fill daily on whether they used the gel consistently every day twice a day for 2 weeks. Patients were also instructed to return the container of gel on the day of follow-up.
Trial: NCT00320580
Drug: norelgestromin/ethinyl estradiol
RxNorm normalized name: norelgestromin/ethinyl estradiol 150 mcg-35 mcg/24 hour TRANSDERM PATCH, TRANSDERMAL WEEKLY
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04933058
Drug: IV acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pain management
Trial: NCT04933058
Drug: IV fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Pain management
Trial: NCT05248022
Drug: Programmed Cell Death Protein 1 Inhibitor
RxNorm normalized name: Programmed cell death protein 1 inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Programmed cell death protein 1 inhibitor fixation was treated with sintilimab (Xinda Biopharmaceutical Co., Ltd.). It is administered by intravenous infusion, and the recommended dose is 200 mg, given once every 21 days. The medication will last for two years until disease progression or intolerable toxicity occurs. During immunotherapy, immunosuppressive agents will not be replaced and the dose will not be adjusted.
Trial: NCT06033521
Drug: Menopausal hormone therapy Intervention Type: Drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects who were newly diagnosed menopausal symptoms between 01 Jan 2012 and 31 Dec 2019, and were followed up for 12 months at least in the HIRA claims database
Trial: NCT05860400
Drug: Secondary prevention for atherosclerotic coronary artery disease
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiplatelet therapy, as well as medications for control of heart rate, blood pressure, low-density lipoprotein cholesterol, and blood glucose
Trial: NCT05860400
Drug: Immunosuppressive therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucocorticoids and/or immunosuppressive agents
Trial: NCT05860400
Drug: Supportive therapies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medical interventions for prevention and treatment of the side effects of the above treatment, such as abnormal liver function, hypocalcemia, hypokalemia, peptic ulcer, infection, et al.
Trial: NCT04745988
Drug: Fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Levofolinate will be administered at a dose of 2600mg/m\^2 as a IV infusion, Q2W.
Trial: NCT04630886
Drug: Lidocaine Epinephrine
RxNorm normalized name: epinephrine / lidocaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: subcutaneous injection of 1% lidocaine mixed with 1:200,000 epinephrine
Trial: NCT05397405
Drug: PCSK9 inhibitor
RxNorm normalized name: PCSK9 inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The aim is to improve blood lipid management by using atorvastatin 20-40mg or rosuvastatin 10-20mg or simvastatin 20-40mg and PCSK9 inhibitors for 6-12 months
Trial: NCT05896124
Drug: 2mg CS0159
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral QD
Trial: NCT05896124
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral QD
Trial: NCT06334315
Drug: Desogestrel / Ethinyl Estradiol Pill
RxNorm normalized name: desogestrel / ethinyl estradiol Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard pill packs containing 21 active pills and 7 placebo pills
Trial: NCT05199272
Drug: 23ME-00610
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 23ME-00610 given by IV infusion
Trial: NCT05718518
Drug: ASC11 tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Part 1: Subjects will receive ASC11 tablets on single ascending doses with proposed dose levels of ASC11 tablets: 100mg (cohort 1), 200 mg (cohort 2), 400mg (cohort 3) and 800 mg (cohort 4).~Part 2: Subjects will receive ASC11tablets 100 to 300 mg (including 3 cohorts) and ASC11 tablets 300 mg(cohort 4) twice daily (BID) for 5 consecutive days and receive a single dose in the early morning of Day 6.~Part 3: Subjects will be randomized to receive ASC11 tablets two single 200 mg or 300 mg doses (fed or fasted)
Trial: NCT05718518
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Part 1 and 2: Subjects will be randomized to receive placebo.
Trial: NCT05718518
Drug: RTV tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Part 1: Subjects will receive RTV tablets on 100 mg (cohort 1-4). Part 2: Subjects will receive RTV tablets 100 mg (including 3 cohorts) twice daily (BID) for 5 consecutive days and receive a single dose in the early morning of Day 6.~Part 3: Subjects will be randomized to receive two single 100 mg doses (fed or fasted)
Trial: NCT05460000
Drug: 3 cycles chemotherapy instead of 6 cycles chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: We hypothesise that recurrence free survival in patients receiving 3 cycles of chemotherapy followed by maintenance with niraparib is not inferior to 6 cycles of chemotherapy followed by niraparib in advanced HRDpositive high-grade ovarian cancer patients with no residual tumor mass following primary tumor debulking.
Trial: NCT05460000
Drug: 6 cycles chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard chemotherapy as comparator
Trial: NCT05715346
Drug: LEV102 1.0%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxymetazoline ophthalmic gel
Trial: NCT05715346
Drug: LEV102 2.0%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxymetazoline ophthalmic gel
Trial: NCT05715346
Drug: Vehicle
RxNorm normalized name: Drug vehicle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle ophthalmic gel
Trial: NCT02545127
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo nasal spray, 2 sprays with 1 spray in each nostril administered 6 to 8 times/day (Day 1 to Day 14).
Trial: NCT05343507
Drug: Ketalar 50 MG/ML Injectable Solution
RxNorm normalized name: Ketalar 50 MG/ML Injectable Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous solution (other info already provided)
Trial: NCT05343507
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline Solution
Trial: NCT05564923
Drug: there is no intervention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: there is no intervention
Trial: NCT05040464
Drug: AZA capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral AZA capsules at a daily dose of 2.5 mg per kilogram,
Trial: NCT05575427
Drug: Minocycline
RxNorm normalized name: Minocycline
DrugBank: Minocycline (DB01017)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The patients will receive minocycline oral between 7-28 days
Trial: NCT05575427
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsule without active compound
Trial: NCT05244577
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo,Ondansetron,Dexamethasone,Fosaprepitant
Trial: NCT01341548
Drug: Civamide nasal solution 0.01%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20ug/dose, BID for 7 days 0.1 ml to each nostril
Trial: NCT05333744
Drug: Recombinant Human TPO
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rhTPO im, 300U/kg per day for 2 weeks, if response (Plt 30-100×100\^g/L), taper to 300U/kg for twice per week until 6 weeks after delivery; if not response, drug withdrawal.
Trial: NCT06202989
Drug: Multiprofen-CC™ plus standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiprofen-CC™ \[ketoprofen (10%), baclofen (5%), amitriptyline (2%), and lidocaine (5%)\] Dose: 1.0g, 3 times per day for 6 weeks after surgery
Trial: NCT04819620
Drug: PN-232
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active Drug
Trial: NCT04819620
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching Placebo
Trial: NCT05829317
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9% NaCl
Trial: NCT04771871
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide is a cytoxic drug indicated for the treatment of many malignancies including breast cancer
Trial: NCT05529173
Drug: 0.9% NaCl Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nasal swab stick application of 0.9% NaCl Solution prior to surgery
Trial: NCT06150014
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TQA3605 placebo tablets were orally administered on an empty stomach (at least 2 hours before or after meals) with warm.
Trial: NCT06150014
Drug: TQA3605 tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TQA3605 inhibits viral replication.
Trial: NCT06232421
Drug: Foscelantan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Foscelantan, medicinal plate 4.0x5.0 cm in package No. 1 produced by UNITEHPROM BSU, Republic of Belarus
Trial: NCT05013229
Drug: IcoSema
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive a once weekly subcutanous (s.c.) injection of IcoSema, on the same day every week for 52 weeks.
Trial: NCT06054464
Drug: PC14586
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Part 1 and Part 2: Single, oral dose of PC14586 on day 1 and single, oral dose of PC14586 on day 14.
Trial: NCT04667429
Drug: HEC83518
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HEC83518 will be taken orally before sleep for 15 days
Trial: NCT04667429
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The placebo will be administered before sleep for 15 days.
Trial: NCT05095337
Drug: [14C]SHR1459
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive single dose of orally \[14C\]SHR1459 on Day 1.
Trial: NCT05177263
Drug: 10% Oral Dextrose Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10% Oral Dextrose Solution
Trial: NCT05177263
Drug: 20% Oral Dextrose Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20% Oral Dextrose Solution
Trial: NCT05177263
Drug: 30% Oral Dextrose Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30% Oral Dextrose Solution
Trial: NCT03724227
Drug: ACE-011
RxNorm normalized name: dibucaine 0.011 MG/MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACE-011 will be administered subcutaneous injection
Trial: NCT04776252
Drug: MK-8591A
RxNorm normalized name: vitamin MK 7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FDC tablet of 100 mg doravirine, 0.75 mg islatravir taken orally, once daily for up to 192 weeks
Trial: NCT05516966
Drug: HRS9531
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administrated SC
Trial: NCT05516966
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administrated SC
Trial: NCT06260748
Drug: Chenodeoxycholic acid
RxNorm normalized name: Chenodeoxycholic acid
DrugBank: Chenodeoxycholic acid (DB06777)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250mg capsules
Trial: NCT06260748
Drug: Chenodeoxycholic acid Placebo
RxNorm normalized name: chenodeoxycholic acid
DrugBank: Chenodeoxycholic acid (DB06777)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to match
Trial: NCT05107934
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9% Sodium Chloride solution for Injection
Trial: NCT04895280
Drug: Ketorolac
RxNorm normalized name: Ketorolac
DrugBank: Ketorolac (DB00465)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ketorolac: will receive an injection of 4 cc 0.25% Marcaine without epinephrine and 30 mg ketorolac x 1
Trial: NCT06355687
Drug: Melatonin
RxNorm normalized name: Melatonin
DrugBank: Melatonin (DB01065)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Obese patients undergoing laparoscopic cholecystectomy will receive melatonin oral (0.2 mg /kg) 45 minutes before general anesthesia.
Trial: NCT04662632
Drug: Standard of Care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Forty-two days (minimum) systemic antibiotic administration adjuvant to two-stage exchange arthroplasty with temporary antibiotic-impregnated cement spacer per standard of care. Antibiotics will be selected by treatment provider and administered in accordance with national and local treatment guidelines.
Trial: NCT04865458
Drug: HEC89736
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HEC89736 tablets QD every 28 days for each cycle
Trial: NCT05775575
Drug: TQB3909 tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TQB3909 is an inhibitor targeting BCL-2 protein
Trial: NCT03547232
Drug: Indomethacin SR
RxNorm normalized name: Indomethacin SR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indomethacin SR 50mg given q12h from admission day 1 to day 7
Trial: NCT03547232
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Similar shape and size suppositories (Placebos) without indomethacin given q12h from admission day 1 to day 7
Trial: NCT06131593
Drug: TAPB with methylprednisolone as an adjuvant to local anesthetics
RxNorm normalized name: Aldex AN
DrugBank: Doxylamine (DB00366)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: patients will receive TAPB with methylprednisolone as an adjuvant to bupivacaine and lidocaine local anesthetics
Trial: NCT06453876
Drug: Heparin
RxNorm normalized name: Heparin
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Active comparator
Trial: NCT05784597
Drug: [68Ga]Ga-OncoFAP administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All patients will receive a single intravenous bolus administration of 250 MBq (225 - 275 MBq)
Trial: NCT04595370
Drug: AZD9977
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive AZD9977 as per the arms they are randomized.
Trial: NCT05034887
Drug: T-DXd, Durvalumab and Capecitabine Combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administer each cycle over 21 days. T-DXd is administered by intravenous infusion at 5.4 mg/kg every 21 days (every 3 weeks). Capecitabine is given at 750 mg/m2 BID, taken orally for 14 days, followed by a drug holiday from the evening of Day 15 to the morning of Day 22 (Day 1 of the next cycle). Durvalumab is administered at 1500 mg by intravenous infusion over 60 minutes every 21 days (every 3 weeks). As neoadjuvant chemotherapy, administer T-DXd, Capecitabine, and Durvalumab in combination on a q3w schedule for 3 cycles. As adjuvant chemotherapy consists of T-DXd, Capecitabine, and Durvalumab in combination on a q3w schedule for 3 cycles, followed by Durvalumab monotherapy on a q4w schedule until 10 cycles are completed.
Trial: NCT05014542
Drug: Conventional Medical Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants could take their standard conventional medical treatment or analgesics. Analgesics therapy is prescribed by their general practitioner. The dose of analgesics could be modified according to participants' symptoms intensity.
Trial: NCT06157827
Drug: LBL-024 for Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Initial dose-MTD; Q3W; intravenous infusion
Trial: NCT06563349
Drug: Intravenous magnesium sulfate
RxNorm normalized name: immunoglobulins, intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraoperative intravenous magnesium sulfate infusion.
Trial: NCT06462573
Drug: general anaethesia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: which patients will undergo ESWL under systemic analgesia. The latter will be achieved using one gram of paracetamol IV infusion at the beginning of the procedure.~In case of unsatisfactory pain control in either group, systemic analgesia using IV Ketorolac injection will be used on demand or the required dose will be recorded at the end of the session.